Vise Technologies Inc. Buys 30,735 Shares of Sanofi $SNY

Vise Technologies Inc. raised its stake in shares of Sanofi (NASDAQ:SNY) by 136.1% in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 53,313 shares of the company’s stock after purchasing an additional 30,735 shares during the period. Vise Technologies Inc.’s holdings in Sanofi were worth $2,584,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors have also made changes to their positions in the stock. Sittner & Nelson LLC boosted its holdings in shares of Sanofi by 100.0% during the 4th quarter. Sittner & Nelson LLC now owns 2,000 shares of the company’s stock valued at $96,000 after purchasing an additional 1,000 shares during the last quarter. Cibc World Market Inc. boosted its holdings in shares of Sanofi by 0.5% during the 4th quarter. Cibc World Market Inc. now owns 376,597 shares of the company’s stock valued at $18,250,000 after purchasing an additional 1,781 shares during the last quarter. Sivia Capital Partners LLC boosted its holdings in shares of Sanofi by 30.7% during the 4th quarter. Sivia Capital Partners LLC now owns 7,642 shares of the company’s stock valued at $370,000 after purchasing an additional 1,797 shares during the last quarter. Pinnacle West Asset Management Inc. boosted its holdings in shares of Sanofi by 7.4% during the 4th quarter. Pinnacle West Asset Management Inc. now owns 6,175 shares of the company’s stock valued at $299,000 after purchasing an additional 425 shares during the last quarter. Finally, WCG Wealth Advisors LLC boosted its holdings in shares of Sanofi by 132.7% during the 4th quarter. WCG Wealth Advisors LLC now owns 61,255 shares of the company’s stock valued at $2,969,000 after purchasing an additional 34,931 shares during the last quarter. Institutional investors own 14.03% of the company’s stock.

Sanofi Stock Performance

Sanofi stock opened at $45.02 on Friday. The company has a debt-to-equity ratio of 0.17, a current ratio of 1.01 and a quick ratio of 0.22. Sanofi has a 1-year low of $42.28 and a 1-year high of $52.68. The firm has a market capitalization of $109.15 billion, a P/E ratio of 12.58, a price-to-earnings-growth ratio of 1.11 and a beta of 0.34. The company’s 50-day moving average is $45.45 and its 200 day moving average is $46.76.

Sanofi Increases Dividend

The company also recently disclosed an annual dividend, which was paid on Wednesday, June 3rd. Investors of record on Monday, May 4th were given a $2.4225 dividend. This is an increase from Sanofi’s previous annual dividend of $2.04. The ex-dividend date of this dividend was Monday, May 4th. This represents a yield of 559.0%. Sanofi’s dividend payout ratio is currently 49.16%.

Wall Street Analysts Forecast Growth

SNY has been the subject of several research reports. Sanford C. Bernstein raised shares of Sanofi to a “strong-buy” rating in a report on Thursday, March 19th. BNP Paribas Exane downgraded shares of Sanofi from an “outperform” rating to a “neutral” rating and set a $50.00 price target for the company. in a report on Monday, April 20th. Argus raised shares of Sanofi to a “strong-buy” rating in a report on Monday, April 27th. Morgan Stanley set a $52.00 price target on shares of Sanofi in a report on Friday, May 1st. Finally, Weiss Ratings raised shares of Sanofi from a “sell (d+)” rating to a “hold (c-)” rating in a report on Wednesday, May 13th. Two investment analysts have rated the stock with a Strong Buy rating, three have assigned a Buy rating and ten have issued a Hold rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Hold” and a consensus target price of $51.00.

Sanofi Profile

Sanofi (NASDAQ:SNY) is a multinational pharmaceutical company headquartered in France that researches, develops, manufactures and markets prescription medicines, vaccines and consumer healthcare products. The company operates across multiple therapeutic areas, including immunology, rare diseases, oncology, cardiovascular and metabolic diseases, and vaccines through its Sanofi Pasteur division. Sanofi sells products to hospitals, clinics, governments and retail pharmacies, with a broad global footprint and significant presence in Europe, North America and emerging markets.

Key commercial offerings include specialty biologics and established small-molecule medicines.